NPX387 / NextPoint - LARVOL DELTA

NextPoint Therapeutics to Showcase Pioneering Preclinical Data on NPX125, a Novel B7-H7 Targeted Antibody-Drug Conjugate (ADC) at AACR Annual Meeting 2025 (Businesswire) - "NPX125, which utilizes NextPoint's proprietary linker technology paired with a clinically validated topoisomerase 1 inhibitor payload in a DAR8 (drug-antibody ratio) format, is initiating IND-enabling work with an anticipated IND filing in mid-2026....NPX125 via its interaction with B7-H7 demonstrated efficient internalization across many different tumor cell lines; Showed both direct and bystander cytotoxic activity, critical for addressing tumor heterogeneity; NPX125 demonstrated superior serum stability in rat pharmacokinetic studies; Robust developability profile due to antibody selection and unique linker properties....NextPoint will also present three additional posters at AACR showcasing its comprehensive approach to targeting the B7-H7 axis."

IND • Preclinical • Solid Tumor

B7-H7-CD3 bispecific T cell engaging antibodies demonstrate potent anti-tumor activity in B7-H7+ preclinical tumor models (AACR 2025) - "These data demonstrate that B7-H7 represents a novel tumor associated antigen for CD3 bispecific T cell engagement that can induce potent T cell-mediated anti-tumor immunity."

Preclinical • Oncology • HHLA2